Related Experiment Video
Updated: Feb 1, 2026

Microinjectrode System for Combined Drug Infusion and Electrophysiology
Published on: November 13, 2019
Strategies of Combination Drug Delivery for Immune Checkpoint Blockades
Huitong Ruan1,2,3,4, Linlin Bu2,3, Quanyin Hu2,3
1Department of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Fudan University, Shanghai, 201203, China.
Abstract:
The past few years have witnessed vast clinical accomplishments of immune checkpoint blockades (ICB), which block the regulatory receptor expressed on immune cells or tumor cells to prevent the suppression of antitumor cytotoxic T-cell responses. Despite this, limitations still exist, such as low objective response rate (ORR) and the risk of immune-related side effects. To address these issues, combination treatment strategies are vastly explored and recommended. This review summarizes recent advances in combination of ICB with therapies that participate in different stages of cancer immune cycle, including tumor antigen release, tumor antigen presentation, T-cell activation, recognition of cancer cells by T-cells, and tumor-killing activity. Challenges and potential opportunities of combination approaches in this field are also discussed.
Insights
Immune checkpoint blockades (ICB) show promise but have limitations. Combining ICB with other cancer therapies targeting the immune cycle may improve response rates and manage side effects.
Area of Science:
- Immunology
- Oncology
- Cancer Therapy
Background:
- Immune checkpoint blockades (ICB) have advanced cancer treatment by blocking regulatory receptors to enhance antitumor T-cell responses.
- Limitations of ICB include low objective response rates (ORR) and immune-related side effects.
- Combination treatment strategies are crucial for overcoming ICB limitations.
Purpose of the Study:
- To review recent advancements in combining ICB with therapies targeting various stages of the cancer immune cycle.
- To discuss the challenges and opportunities associated with ICB combination approaches.
Main Methods:
- Literature review of recent studies on ICB combination therapies.
- Analysis of therapies targeting different phases of the cancer immune cycle: antigen release, presentation, T-cell activation, recognition, and tumor killing.
Main Results:
- ICB combination strategies are being explored across all stages of the cancer immune cycle.
- These combinations aim to enhance antitumor immunity and mitigate adverse effects.
- The review highlights progress in integrating ICB with diverse therapeutic modalities.
Conclusions:
- Combining ICB with other cancer therapies holds significant potential for improving treatment efficacy.
- Addressing challenges in combination strategies is key to realizing their full therapeutic benefit.
- Further research into ICB combinations offers opportunities to advance cancer immunotherapy.
More Related Videos
10:33Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells
Published on: November 18, 2022
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
Related Concept Videos
Neuromuscular Junction And Blockade
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Drug Delivery: Overview
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Drug Delivery: Enteral Route
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...